EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study

Akira Mima iD, Yasuhiro Horii

Endocrinology, Diabetes & Metabolism · 2024

DOI: 10.1002/edm2.489 ↗

At a glance

Journal article in Endocrinology, Diabetes & Metabolism, 2024. Written by Akira Mima and 1 co-authors. Institution: Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Renal Dialysis, Glycemic Control. Cited 12 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY 4.0). Funded by: Japan Society for the Promotion of Science.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight‐loss effect primarily targets fat reduction; however, such effect on patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) has not been reported.

Methods

Nine patients with CKD undergoing HD received weekly tirzepatide doses (2.5–7.5 mg) once a week. Evaluations encompassed tirzepatide's impact on dry weight (DW) and body composition assessed at baseline and study conclusion using bioelectrical impedance analysis. This longitudinal study included nine patients, with a median age of 53 years and median HD duration of 4 years.

Results

Tirzepatide treatment significantly decreased glycated albumin compared with the value at baseline (22.7 ± 5.4 vs. 18.3 ± 2.5%, p = 0.028, respectively). Significant reductions were observed in DW (−1.0 kg, p = 0.024) and body mass index (−0.6 kg/m 2 , p = 0.050) following tirzepatide administration. Total fat mass was also reduced, but not significantly (− 2.51% from baseline, p = 0.214). In contrast, skeletal muscle mass was not decreased (−1.02% from baseline, p = 0.722). No serious side effects other than nausea were observed during the study period.

Conclusion

Tirzepatide effectively provides good glycaemic control in T2DM patients undergoing HD, decreasing DW by reducing body fat mass without increasing frailty risk.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Renal DialysisGlycemic ControlHumansMiddle AgedMaleFemaleRetrospective StudiesAdultAgedBody CompositionRenal Insufficiency, ChronicBlood GlucoseLongitudinal StudiesHypoglycemic Agents

Author keywords

dry weighthemodialysistirzepatidetype 2 diabetes

Substances

Blood GlucoseHypoglycemic Agents

Authors and institutions

  • Department of Nephrology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Seiwadai Clinic, Nara, Japan.

ORCID profiles: Akira Mima

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Mima, A., & Horii, Y. (2024). Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.489

Vancouver

Mima A, Horii Y. Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study. Endocrinology, Diabetes & Metabolism. 2024. doi:10.1002/edm2.489

BibTeX
@article{Mima2024,
  author = {Mima, Akira and Horii, Yasuhiro},
  title = {Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2024},
  doi = {10.1002/edm2.489}
}
Start for free →